Patents by Inventor Randal Robert KETCHUM

Randal Robert KETCHUM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230335222
    Abstract: Amino acid sequences of proteins can be produced using an autoencoder. For example, amino acid sequences of variant proteins can be produced by an autoencoder that is fed an amino acid sequence of a base protein as input. A decoding component of the autoencoder can include at least one or more components of a generative adversarial network.
    Type: Application
    Filed: September 21, 2021
    Publication date: October 19, 2023
    Inventors: Jeremy Martin Shaver et al., Tileli Amimeur, Randal Robert Ketchum
  • Patent number: 10851144
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: December 1, 2020
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Ai Ching Lim, Randal Robert Ketchum, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • Publication number: 20200024319
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: May 4, 2016
    Publication date: January 23, 2020
    Applicant: AMGEN INC.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Ai Ching LIM, Randal Robert KETCHUM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI